½ÃÀ庸°í¼­
»óǰÄÚµå
1486406

¼¼°èÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå ±Ô¸ð Á¶»ç : ±â¼úº°, µ¶¼º Æò°¡ÁöÇ¥º°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)

Global Early Toxicity Testing Market Size study, by Technique, by Toxicity Endpoint, by End User and Regional Forecasts 2022-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è Ãʱ⠵¶¼º ½ÃÇè ½ÃÀåÀº 2023³â ¾à 12¾ï 1,000¸¸ ´Þ·¯ ±Ô¸ð¿¡ ´ÞÇßÀ¸¸ç, ¿¹Ãø ±â°£ÀÎ 2024³âºÎÅÍ 2032³â±îÁö 8.53% ÀÌ»óÀÇ °ßÁ¶ÇÑ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.

Ãʱ⠵¶¼º ½ÃÇèÀº ½Å¾à °³¹ß °úÁ¤¿¡¼­ Áß¿äÇÑ ´Ü°èÀ̸ç, »õ·Î¿î È­ÇÕ¹°À̳ª ¹°ÁúÀÌ »ý¹°Ã¼¿¡ ¹ÌÄ¥ ¼ö ÀÖ´Â ÀáÀçÀûÀÎ ºÎÀÛ¿ëÀ» Æò°¡ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ÀÌ ¿¹ºñ Æò°¡´Â ¾ÈÀü¼º ¹®Á¦¸¦ ÆÄ¾ÇÇÏ¿© ÈÄ¼Ó ¿¬±¸°³¹ß¿¡ µµ¿òÀ» ÁÝ´Ï´Ù. Ãʱ⠵¶¼º½ÃÇèÀ» ÅëÇØ R&D´Â ÀǾàǰ Èĺ¸¹°ÁúÀ» Ãß°¡ °³¹ß ´Ü°è·Î ³Ñ¾î°¡±â Àü¿¡ À§ÇèÀ» ÁÙÀÌ°í ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» ÃÖÀûÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼¼°è Ãʱ⠵¶¼º ½ÃÇè ½ÃÀåÀº ½ÅÈï±¹µéÀÇ ¿¬±¸°³¹ß¿¡ ´ëÇÑ °ü½É Áõ°¡¿Í »ý¸íÀ» À§ÇùÇÏ´Â Áúº´¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ ÀǾàǰ ¹× ±â¼ú °³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡·Î ÀÎÇØ À¯¸ÁÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

´ç´¢º´, ¾Ï, ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ »õ·Ó°í È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ ¾ÈÀü¼ºÀ» º¸ÀåÇϱâ À§ÇØ ±¤¹üÀ§ÇÑ µ¶¼º ½ÃÇè°¡ ÇÊ¿äÇØÁü¿¡ µû¶ó Àü ¼¼°è Ãʱ⠵¶¼º ½ÃÇè ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãʱ⠵¶¼º ½ÃÇè ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä ±ÞÁõÀº ¼ÒºñÀÚ Àνİú ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã·Î ÀÎÇØ ½Äǰ °¡°ø ¹× ¾ÈÀü º¸Àå¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´õ¿í ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª Ãʱ⠵¶¼º ½ÃÇè°ú °ü·ÃµÈ ³ôÀº ºñ¿ë, ƯÈ÷ ´Ù¾çÇÑ »ý¹°Ã¼¿Í ¿©·¯ Á¾¸»Á¡À» Æ÷ÇÔÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÇèÀÇ °æ¿ì, ƯÈ÷ ÀڱݷÂÀÌ ºÎÁ·ÇÑ Áß¼Ò±â¾÷¿¡°Ô´Â Å« À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹Ì±¹ FDA ¹× À¯·´ÀǾàǰû(EMA)°ú °°Àº ±â°üÀÇ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀº ½Å¾à ½ÂÀÎ °úÁ¤À» Áö¿¬½ÃŰ°í ½ÃÀå ÁøÀÔÀ» Áö¿¬½ÃÅ´À¸·Î½á ¼¼°è Ãʱ⠵¶¼º ½ÃÇè ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

À̹ø Ãʱ⠵¶¼º ½ÃÇè ¼¼°è ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, Áß³²¹Ì, ±âŸ Áö¿ªÀ̸ç, 2023³â¿¡´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå Å« Áö¿ª ½ÃÀåÀ¸·Î ºÎ»óÇß½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¬±¸ °³¹ß(R&D) Ȱµ¿¿¡ ´ëÇÑ °­·ÂÇÑ ÁýÁß°ú ÀϺ», Çѱ¹, È£ÁÖ µîÀÇ ±¹°¡¿¡¼­ÀÇ ºÎ¹® È®´ë·Î ÀÎÇØ Ãʱ⠵¶¼º ½ÃÇè(ETT) »ê¾÷À» ¼±µµÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù. ¶ÇÇÑ Áß±¹, Àεµ, ÀϺ», Çѱ¹ µî ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀϺΠ±¹°¡¿¡¼­ ³úÁ¹Áß ¹ß»ý·üÀÌ Áõ°¡Çϸ鼭 ETT »ê¾÷ÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ³úÁ¹ÁßÀº ³úÁ¹Áß È¯ÀÚ¸¦ À§ÇÑ ½Å¾à ¹× Ä¡·á¹ý °³¹ß¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ Ãʱ⠵¶¼º ½ÃÇè¿¡ ÀÖ¾î Áß¿äÇÑ °ü½É ºÐ¾ßÀÔ´Ï´Ù. National Center for Biotechnology Information¿¡ µû¸£¸é, 2022³â 3¿ù ÇöÀç 40¼¼ ÀÌ»ó Áß±¹ÀÎÀÇ ³úÁ¹Áß ¹ßº´ °Ç¼ö´Â 3,400¸¸ °Ç, À¯º´ÀÚ ¼ö´Â 1,780¸¸ ¸í, ³úÁ¹Áß »ç¸ÁÀÚ ¼ö´Â 230¸¸ ¸í¿¡ ´ÞÇÕ´Ï´Ù. ÇÑÆí, ºÏ¹Ì´Â 2024³âºÎÅÍ 2032³â±îÁö ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â Áö¿ªÀÔ´Ï´Ù.

ÀÌ º¸°í¼­¿¡ Æ÷ÇÔµÈ ÁÖ¿ä ½ÃÀå ±â¾÷

  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • Bruker Corporation
  • Charles River Laboratories International Inc.
  • Danaher Corporation
  • Enzo Biochem Inc.
  • Eurofins Scientific SE
  • Evotec A.G.
  • Merck KGaA
  • PerkinElmer Inc.

¸ñÂ÷

Á¦1Àå ¼¼°èÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå Á¤ÀÇ¿Í Á¶»ç °¡Á¤

  • Á¶»ç ¸ñÀû
  • ½ÃÀå Á¤ÀÇ
  • Á¶»ç °¡Á¤
    • Æ÷ÇÔ »çÇס¤Á¦¿Ü »çÇ×
    • Á¦ÇÑ»çÇ×
    • °ø±ÞÃø ºÐ¼®
      • ÀÔ¼ö °¡´É¼º
      • ÀÎÇÁ¶ó
      • ±ÔÁ¦ ȯ°æ
      • ½ÃÀå °æÀï
      • °æÁ¦¼º(¼ÒºñÀÚÀÇ °üÁ¡)
    • ¼ö¿äÃø ºÐ¼®
      • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
      • ±â¼ú Áøº¸
      • ģȯ°æ
      • ¼ÒºñÀÚ Àǽİú ¼ö¿ë
  • ÃßÁ¤ ¹æ¹ý
  • Á¶»ç ´ë»ó ¿¬µµ
  • ÅëÈ­ ȯ»êÀ²

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • Ãʱ⠵¶¼º ½ÃÇè ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2022-2032³â)
  • Áö¿ªº° °³¿ä
  • ºÎ¹®º° °³¿ä
    • ±â¼úº°
    • µ¶¼º ¿£µåÆ÷ÀÎÆ®º°
    • ÃÖÁ¾»ç¿ëÀÚº°
  • ÁÖ¿ä µ¿Çâ
  • ºÒȲÀÇ ¿µÇâ
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð°ú Á¦¾È

Á¦3Àå Ãʱ⠵¶¼º ½ÃÇè ¼¼°è ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå °úÁ¦
  • ½ÃÀå ±âȸ

Á¦4Àå Ãʱ⠵¶¼º ½ÃÇè ¼¼°è ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷ °£ÀÇ °æÀï °ü°è
    • Porter's Five Forces ¸ðµ¨·ÎÀÇ ¹Ì·¡ÁöÇâÀû Á¢±Ù¹ý
    • Porter's Five ForcesÀÇ ¿µÇ⠺м®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • ÆÄ±«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ °üÁ¡
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð°ú Á¦¾È

Á¦5Àå Ãʱ⠵¶¼º ½ÃÇè ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ±â¼úº°, 2022-2032³â

  • Àκñº¸
  • ÀκñÆ®·Î
  • ÀνǸ®ÄÚ

Á¦6Àå Ãʱ⠵¶¼º ½ÃÇè ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : µ¶¼º ¿£µåÆ÷ÀÎÆ®º°, 2022-2032³â

  • À¯ÀüÀÚ µ¶¼º
  • °æÇÇ µ¶¼º
  • ÇǺΠµ¶¼º
  • ´« µ¶¼º
  • ±¤µ¶¼º
  • ±âŸ

Á¦7Àå Ãʱ⠵¶¼º ½ÃÇè ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2022-2032³â

  • ÀǾàǰ »ê¾÷
  • È­Àåǰ »ê¾÷
  • È­ÇÐ »ê¾÷
  • ½Äǰ »ê¾÷
  • ±âŸ

Á¦8Àå Ãʱ⠵¶¼º ½ÃÇè ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°, 2022-2032³â

  • ºÏ¹ÌÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • ¹Ì±¹
      • ±â¼ú ³»¿ª ±Ô¸ð¿Í ¿¹Ãø, 2022-2032³â
      • µ¶¼º ¿£µåÆ÷ÀÎÆ® ³»¿ª ±Ô¸ð¿Í ¿¹Ãø, 2022-2032³â
      • ÃÖÁ¾ ¿ëµµ ³»¿ª ±Ô¸ð¿Í ¿¹Ãø, 2022-2032³â
    • ij³ª´ÙÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
  • À¯·´ÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • ¿µ±¹ÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • µ¶ÀÏÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • ÇÁ¶û½ºÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • ½ºÆäÀÎÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • ÀÌÅ»¸®¾ÆÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • ±âŸ À¯·´ÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • Áß±¹ÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • ÀεµÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • ÀϺ»ÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • È£ÁÖ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • Çѱ¹ÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • ºê¶óÁúÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • ¸ß½ÃÄÚÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • »ç¿ìµð¾Æ¶óºñ¾ÆÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹ÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå

Á¦9Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Agilent Technologies Inc.
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ °¡¿ë¼º¿¡ µû¶ó ´Ù¸§)
      • Á¦Ç° °³¿ä
      • ½ÃÀå Àü·«
    • Bio-Rad Laboratories Inc.
    • Bruker Corporation
    • Charles River Laboratories International Inc.
    • Danaher Corporation
    • Enzo Biochem Inc.
    • Eurofins Scientific SE
    • Evotec A.G.
    • Merck KGaA
    • PerkinElmer Inc.

Á¦10Àå Á¶»ç °úÁ¤

  • Á¶»ç °úÁ¤
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
ksm 24.06.04

Global Early Toxicity Testing Market is valued at approximately USD 1.21 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 8.53% over the forecast period 2024-2032. Early toxicity testing is a critical phase in the drug development process, aimed at assessing the potential adverse effects of new compounds or substances on living organisms. This preliminary evaluation helps identify safety concerns and informs subsequent research and development efforts. By conducting early toxicity testing, researchers can mitigate risks and optimize the safety profile of pharmaceutical candidates before advancing them to further stages of development. The Global Early Toxicity Testing Market shows promising growth due to the heightened emphasis of developing countries on R&D and increased investments in innovative drug and technology development for life-threatening diseases.

The increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders has heightened the demand for new and efficacious treatments, necessitating extensive toxicological testing to ensure their safety driving the growth of the Global Early Toxicity Testing Market. This surge in demand for early toxicity testing services is further propelled by the rising need for food processing and safety assurance, driven by consumer awareness and regulatory scrutiny. However, the high costs associated with early toxicity testing, particularly for comprehensive studies involving diverse organisms and multiple endpoints, pose a significant barrier, particularly for smaller companies with limited financial resources. Moreover, stringent regulatory requirements set by agencies such as the US FDA and the European Medicines Agency lengthen the approval process for new drugs, potentially impeding Global Early Toxicity Testing Market growth due to delayed market entry.

The key regions considered for the Global Early Toxicity Testing market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, Asia Pacific was the largest regional market. The Asia-Pacific region is poised to lead the Early Toxicity Testing (ETT) industry, driven by its robust focus on Research and Development (R&D) activities and the expanding sector in nations such as Japan, South Korea, and Australia. Furthermore, the increasing incidence of strokes in specific countries within the Asia-Pacific region, including China, India, Japan, and South Korea, is fueling growth in the ETT industry. Stroke represents a critical area of concern for early toxicity testing, as it plays a pivotal role in the development of new drugs and therapies for stroke patients. According to the National Center for Biotechnology Information, as of March 2022, there were 34 million incident cases of stroke, 17.8 million prevalent cases, and 2.3 million deaths from stroke among the Chinese population aged 40 years and older. Whereas, North America is accounted as the fastest growing region over the forecast period of 2024-2032.

Major market player included in this report are:

  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • Bruker Corporation
  • Charles River Laboratories International Inc.
  • Danaher Corporation
  • Enzo Biochem Inc.
  • Eurofins Scientific SE
  • Evotec A.G.
  • Merck KGaA
  • PerkinElmer Inc.

The detailed segments and sub-segment of the market are explained below:

By Technique

  • In Vivo
  • In Vitro
  • In Silico

By Toxicity Endpoint

  • Genotoxicity
  • Dermal Toxicity
  • Skin Toxicity
  • Ocular Toxicity
  • Phototoxicity
  • Others

By End Use

  • Pharmaceutical Industry
  • Cosmetic Industry
  • Chemical Industry
  • Food Industry
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • RoMEA

Years considered for the study are as follows:

  • Historical year - 2022
  • Base year - 2023
  • Forecast period - 2024 to 2032

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1.Global Early Toxicity Testing Market Definition and Research Assumptions

  • 1.1.Research Objective
  • 1.2.Market Definition
  • 1.3.Research Assumptions
    • 1.3.1.Inclusion & Exclusion
    • 1.3.2.Limitations
    • 1.3.3.Supply Side Analysis
      • 1.3.3.1.Availability
      • 1.3.3.2.Infrastructure
      • 1.3.3.3.Regulatory Environment
      • 1.3.3.4.Market Competition
      • 1.3.3.5.Economic Viability (Consumer's Perspective)
    • 1.3.4.Demand Side Analysis
      • 1.3.4.1.Regulatory frameworks
      • 1.3.4.2.Technological Advancements
      • 1.3.4.3.Environmental Considerations
      • 1.3.4.4.Consumer Awareness & Acceptance
  • 1.4.Estimation Methodology
  • 1.5.Years Considered for the Study
  • 1.6.Currency Conversion Rates

Chapter 2.Executive Summary

  • 2.1.Global Early Toxicity Testing Market Size & Forecast (2022- 2032)
  • 2.2.Regional Summary
  • 2.3.Segmental Summary
    • 2.3.1.By Technique
    • 2.3.2.By Toxicity Endpoint
    • 2.3.3.By End User
  • 2.4.Key Trends
  • 2.5.Recession Impact
  • 2.6.Analyst Recommendation & Conclusion

Chapter 3.Global Early Toxicity Testing Market Dynamics

  • 3.1.Market Drivers
  • 3.2.Market Challenges
  • 3.3.Market Opportunities

Chapter 4.Global Early Toxicity Testing Market Industry Analysis

  • 4.1.Porter's 5 Force Model
    • 4.1.1.Bargaining Power of Suppliers
    • 4.1.2.Bargaining Power of Buyers
    • 4.1.3.Threat of New Entrants
    • 4.1.4.Threat of Substitutes
    • 4.1.5.Competitive Rivalry
    • 4.1.6.Futuristic Approach to Porter's 5 Force Model
    • 4.1.7.Porter's 5 Force Impact Analysis
  • 4.2.PESTEL Analysis
    • 4.2.1.Political
    • 4.2.2.Economical
    • 4.2.3.Social
    • 4.2.4.Technological
    • 4.2.5.Environmental
    • 4.2.6.Legal
  • 4.3.Top investment opportunity
  • 4.4.Top winning strategies
  • 4.5.Disruptive Trends
  • 4.6.Industry Expert Perspective
  • 4.7.Analyst Recommendation & Conclusion

Chapter 5.Global Early Toxicity Testing Market Size & Forecasts by Technique 2022-2032

  • 5.1.In Vivo
  • 5.2.In Vitro
  • 5.3.In Silico

Chapter 6.Global Early Toxicity Testing Market Size & Forecasts by Toxicity Endpoint 2022-2032

  • 6.1.Genotoxicity
  • 6.2.Dermal Toxicity
  • 6.3.Skin Toxicity
  • 6.4.Ocular Toxicity
  • 6.5.Phototoxicity
  • 6.6.Others

Chapter 7.Global Early Toxicity Testing Market Size & Forecasts by End Use 2022-2032

  • 7.1.Pharmaceutical Industry
  • 7.2.Cosmetic Industry
  • 7.3.Chemical Industry
  • 7.4.Food Industry
  • 7.5.Others

Chapter 8.Global Early Toxicity Testing Market Size & Forecasts by Region 2022-2032

  • 8.1.North America Early Toxicity Testing Market
    • 8.1.1.U.S. Early Toxicity Testing Market
      • 8.1.1.1. Technique breakdown size & forecasts, 2022-2032
      • 8.1.1.2.Toxicity Endpoint breakdown size & forecasts, 2022-2032
      • 8.1.1.3.End Use breakdown size & forecasts, 2022-2032
    • 8.1.2.Canada Early Toxicity Testing Market
  • 8.2.Europe Early Toxicity Testing Market
    • 8.2.1.U.K. Early Toxicity Testing Market
    • 8.2.2.Germany Early Toxicity Testing Market
    • 8.2.3.France Early Toxicity Testing Market
    • 8.2.4.Spain Early Toxicity Testing Market
    • 8.2.5.Italy Early Toxicity Testing Market
    • 8.2.6.Rest of Europe Early Toxicity Testing Market
  • 8.3.Asia-Pacific Early Toxicity Testing Market
    • 8.3.1.China Early Toxicity Testing Market
    • 8.3.2.India Early Toxicity Testing Market
    • 8.3.3.Japan Early Toxicity Testing Market
    • 8.3.4.Australia Early Toxicity Testing Market
    • 8.3.5.South Korea Early Toxicity Testing Market
    • 8.3.6.Rest of Asia Pacific Early Toxicity Testing Market
  • 8.4.Latin America Early Toxicity Testing Market
    • 8.4.1.Brazil Early Toxicity Testing Market
    • 8.4.2.Mexico Early Toxicity Testing Market
    • 8.4.3.Rest of Latin America Early Toxicity Testing Market
  • 8.5.Middle East & Africa Early Toxicity Testing Market
    • 8.5.1. Saudi Arabia Early Toxicity Testing Market
    • 8.5.2. South Africa Early Toxicity Testing Market
    • 8.5.3.Rest of Middle East & Africa Early Toxicity Testing Market

Chapter 9.Competitive Intelligence

  • 9.1.Key Company SWOT Analysis
  • 9.2.Top Market Strategies
  • 9.3.Company Profiles
    • 9.3.1. Agilent Technologies Inc.
      • 9.3.1.1.Key Information
      • 9.3.1.2.Overview
      • 9.3.1.3.Financial (Subject to Data Availability)
      • 9.3.1.4.Product Summary
      • 9.3.1.5.Market Strategies
    • 9.3.2. Bio-Rad Laboratories Inc.
    • 9.3.3.Bruker Corporation
    • 9.3.4.Charles River Laboratories International Inc.
    • 9.3.5.Danaher Corporation
    • 9.3.6.Enzo Biochem Inc.
    • 9.3.7.Eurofins Scientific SE
    • 9.3.8.Evotec A.G.
    • 9.3.9.Merck KGaA
    • 9.3.10.PerkinElmer Inc.

Chapter 10.Research Process

  • 10.1.Research Process
    • 10.1.1.Data Mining
    • 10.1.2.Analysis
    • 10.1.3.Market Estimation
    • 10.1.4.Validation
    • 10.1.5.Publishing
  • 10.2.Research Attributes
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦